Australian IVD sector welcomes rebirth of ANZTPA plan - with caveats
This article was originally published in Clinica
Australia’s in vitro diagnostics (IVD) industry has welcomed the resumption of talks on the creation of a joint Australian and New Zealand agency for the regulation of healthcare products (www.clinica.co.uk, 20 June 2011), but with important caveats.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.